Role of clinical patient- reported outcome and medico economic studies in the public hospital drug formulary decision making process: result of an european survey

Context:Over the past 20 years, drug information has grown rapidly, but little is known of its actual use in hospital decision-making.Objective:To describe the role of clinical studies (CS), patient-reported outcome studies (PROS) and medico-economic studies (MES) in public hospital drug formulary d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health policy (Amsterdam) 2005-02, Vol.71, p.205-212
Hauptverfasser: Hasle-Pham, E., Arnould, B., Spath, Hm, Fallet, A., Duru, Gérard, Marquis, P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Context:Over the past 20 years, drug information has grown rapidly, but little is known of its actual use in hospital decision-making.Objective:To describe the role of clinical studies (CS), patient-reported outcome studies (PROS) and medico-economic studies (MES) in public hospital drug formulary decision-making.Methods:A postal survey was conducted in 400 randomly selected public hospitals stratified by country (France, Germany, The Netherlands and the United Kingdom) and profession (doctor or pharmacist).Results:The participation rate was 78% (143 doctors and 169 pharmacists), and the response rate 44%. Responders were generally interested in CS (86%), PROS (71%) and MES (71%). They reported high but unmet expectations concerning information available on PROS and MES, the methodology of these studies and interpretation of the results.Conclusions:To increase the impact of PROS and MES, we suggest training decision-makers in the study methodology and provide them with support of health and economic experts.
ISSN:0168-8510
DOI:10.1016/j.healthpol.2004.08.007